Management of menopause

American Family Physician

Volumn 55, Issue 5, 1997, Pages 1667-1674

  Hammond, Charles B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; SALCATONIN; SALMONINE; UNCLASSIFIED DRUG;

BREAST CANCER; CALCIUM INTAKE; CANCER RISK; CORONARY ARTERY ATHEROSCLEROSIS; ENDOMETRIUM CANCER; ESTROGEN THERAPY; EXERCISE; FEMALE; HIP FRACTURE; HUMAN; LIFESTYLE; MENOPAUSE; OSTEOPOROSIS; PATIENT COMPLIANCE; REVIEW; UTERUS BLEEDING;

EID: 0030975389     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Projections of the population of the United States: 1977 to 2050. Current Population Reports: population estimates and projections: series P-25; no. 704. Washington, D.C.: Department of Commerce, Bureau of the Census, 1977.
2. Andrews WC, ed. Menopause and hormone replacement: introduction. Obstet Gynecol 1996;87(Suppl 2):1S-54S.
3. Yen SS. The biology of menopause. J Reprod Med 1977;18:287-96.
4. Longcope C. The endocrinology of the menopause. In: Lobo RA, ed. Treatment of the postmenopausal woman: basic and clinical aspects. New York: Raven, 1994:47-53.
5. Coope J, Thomson JM, Poller L. Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975;4:139-43.
6. Steingold KA, Laufer L, Chetkowski RJ, DeFazio JD, Matt DW, Meldrum DR, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-32.
7. Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-5.
8. Clayden JR, Bell JW, Pollard P. Menopausal flushing: a double-blind trial of a non-hormonal medication. Br Med J 1974;1:409-12.
9. Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome. A double-blind evaluation of an autonomic system stabilizer. Obstet Gynecol 1969;33:795-9.
10. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology 1985;10:325-35.
11. Sherwin BB. Hormones, mood, and cognitive functioning in postmenopausal women. Obstet Gynecol 1996;87(2 Suppl):20S-26S.
12. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61.
13. Hui SL, Slemenda CW, Johnston CC Jr. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989;111:355-61.
14. Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB. Bone gain in young adult women. JAMA 1992;268:2403-8.
15. Hammond CB. Menopause and hormone replacement therapy: an overview. Obstet Gynecol 1996; 87(Suppl 2):2S-15S.
16. Smith DM, Nance WE, Kang KW, Christian JC, Johnston CC Jr. Genetic factors in determining bone mass. J Clin Invest 1973;52:2800-8.
17. Riggs BL. Treatment of osteoporosis with sodium fluoride: an appraisal. Bone Miner Res 1983;2:366-93.
18. Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol [Oxf] 1989; 30:435-42.
19. Melton LJ 3d, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33.
20. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759-63.
21. Lindsay R. The menopause and osteoporosis. Obstet Gynecol 1996;87(2 Suppl):16S-19S.
22. Advance report of final mortality statistics, 1989. Hyattsville, Md.: National Center for Health Statistics, 1992:1-47.
23. Wild RA. Estrogen: effects on the cardiovascular tree. Obstet Gynecol 1996;87(2 Suppl):27S-35S.
24. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol 1996;87(2 Suppl):36S-43S.
25. Williams JK, Shively CA, Clarkson TB. Determinants of coronary artery reactivity in premenopausal female cynomolgus monkeys with diet-induced atherosclerosis. Circulation 1994;90:983-7.
26. Spicer DV, Pike MC. Epidemiology of breast cancer. In: Lobo RA, ed. Treatment of the postmenopausal woman: basic and clinical aspects. New York: Raven, 1994:315-24,
27. Armstrong BK. Oestrogen therapy after the menopause - boon or bane? Med J Aust 1988;148: 213-4.
28. Bates SK. Estrogen and breast cancer. J Soc Obstet Gynecol Can 1990;12:9.
29. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.
30. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992;79:286-94.
31. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90 [Published erratum appears in JAMA 1991;266:1362].
32. Gambrell RD Jr. Prevention of endometrial cancer with progestogens. Maturitas 1986;8:159-68.
33. Utian WH, Schiff I. Gallup Survey on women's knowledge, information sources and attitudes to menopause and hormone replacement therapy. Menopause J NAMS 1994;1:39-48.
34. Andrews WC. The transitional years and beyond. Obstet Gynecol 1995;85:1-5.
35. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990;163(5 Pt 1):1438-44.
36. Christiansen C, Overgaard K, eds. Osteoporosis 1990: International Symposium on Osteoporosis, Denmark, 14-20 October 1990. Copenhagen, Denmark: Osteopress, 1990.
37. Hammond CB. Women's concerns with hormone replacement therapy - compliance issues. Fertil Steril 1994;62(6 Suppl 2):157S-160S.
38. Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992;15:151-8.